The biotech industry underestimated how a new political administration would impact the mRNA space. The change in leadership led to significant regulatory uncertainty and a general risk aversion towards mRNA technology, which in turn suppressed faith and funding despite the platform's recent successes.

Historically, America's strength grew by attracting top academics and scientists fleeing oppression, leading to major innovations. Now, by attacking universities and international students, the U.S. is causing this flow of elite human capital to reverse. Top researchers are seeking asylum elsewhere, draining the country of future breakthroughs.

The Trump administration's actions have eroded the long-standing trust that the federal government will provide stable, long-term research funding. This breakdown of the 'social contract' discourages scientists from pursuing ambitious, multi-decade longitudinal studies, which are crucial for major breakthroughs but are now perceived as too risky.

The legal rationale for Anthropic's ban—that any foreign employee poses a risk—threatens the entire U.S. AI ecosystem. With foreign-born researchers comprising up to 40% of top talent, expanding this policy would be "debilitating" for major labs like OpenAI and Anthropic, crippling their innovation capacity.

The greatest threat from the administration's actions isn't budget cuts, but the erosion of trust in the scientific process itself. By creating instability and politicizing advisory bodies, it risks making public skepticism seem rational, a far more damaging long-term legacy.

After advocating for minimal AI regulation, the administration's abrupt action against Anthropic's Fable model signals a chaotic policy reversal. This unpredictable shift from "let it rip" to ad-hoc intervention threatens investment and the future of American AI development by creating an unstable regulatory environment.

An ideologically driven and inconsistent FDA is eroding investor confidence, turning the U.S. into a difficult environment for investment in complex biologics like gene therapies and vaccines, potentially pushing innovation to other countries.

The White House is delaying models like GPT 5.6 through an informal, non-transparent process, approving access customer-by-customer. This arbitrary system, described as an "ad hoc licensing regime," is considered more damaging than predictable red tape because it creates immense uncertainty for developers and businesses.

The industry's negative perception of FDA leadership and regulatory inconsistency is having tangible consequences beyond investment chilling. Respondents report actively moving clinical trials outside the U.S. and abandoning vaccine programs. This self-inflicted wound directly weakens America's biotech ecosystem at the precise moment its race with China is intensifying.